TORONTO, Jan. 17 /PRNewswire-FirstCall/ - Tm Bioscience Corporation , a leader in the commercial genetic testing market, today announced it has signed an agreement to supply Jacobi Medical Center (Bronx, New York) with Tag-It(TM) reagents for use in its Ashkenazi Jewish Panel and Cystic Fibrosis (CF) gene assays.
“Using Tm’s platform approach, we have been able to greatly enhance our genetic screening abilities to the benefit of the large communities we serve. The Tag-It(TM) technology has allowed us to create assays that generate accurate results rapidly while minimizing operator time,” said Dr. Susan Gross, Co-Director of the Division of Reproductive Genetics at Jacobi Medical Center.
Located in the Bronx, Jacobi Medical Center provides quality health care for some 1.2 million Bronx and New York area residents. With more than 500 beds, Jacobi Medical Center has grown into the largest public hospital in the Bronx. It offers a complete range of acute, specialty, general and psychiatric services. Jacobi also operates community-based health care centers that provide general adult and pediatric examinations and health screenings for a variety of concerns, including hypertension, diabetes, breast cancer and prostate cancer.
About Tag-It(TM) reagents and genetic tests
Tm Bioscience’s product menu is focused in the fields of human genetic disorders, pharmacogenetics and infectious disease. The Company has commercialized Analyte Specific Reagents(x) and a series of Tag-It(TM) tests(xx) for a variety of genetic disorders. The Company’s Tag-It(TM) Cystic Fibrosis (CF) Kit is the first multiplexed human disease genotyping test to be cleared by the U.S. Food and Drug Administration (FDA) as an in vitro device (IVD) for diagnostic use in the United States. It has also received the CE Mark, allowing the test to be marketed for diagnostic purposes in the European Union. All genetic tests from Tm Bioscience are based on the Tag-It(TM) Universal Array platform, which utilizes a proprietary universal tag system that allows for easy optimization, product development and expansion. Assays from Tm operate on the Luminex xMAP(R) system, a well-established bead based instrument. Combined, the Universal Array and Luminex instrument enable the rapid production of flexible, high-throughput, low-cost DNA-based tests.
(x) Analyte Specific Reagent. Analytical and performance characteristics are not established.
(xx) For Investigational Use Only. The performance characteristics of these products have not been established
About Tm Bioscience - Putting the Human Genome to Work(TM)
Tm Bioscience is a DNA-based diagnostics company developing a suite of genetic tests. Tm Bioscience’s product pipeline includes tests for genetic disorders, drug metabolism, and infectious diseases. Tm Bioscience is located in Toronto, Ontario. Additional information about Tm Bioscience can be found at www.tmbioscience.com.
The TSX Exchange has not reviewed and does not accept responsibility for
the adequacy or accuracy of this release.
Tm Bioscience
CONTACT: INVESTOR RELATIONS CONTACTS: Tm Bioscience - Canada: James Smith,The Equicom Group, Tel.: (416) 815-0700, Email: jsmith@equicomgroup.com; TmBioscience - U.S.: Sharon Weinstein, Account Supervisor, Euro RSCG LifeNRP, Tel.: (212) 845-4271, Email: sharon.weinstein@eurorscg.com; JacobiMedical Center: Michael Heller, Tel.: (718) 918-3826; To request a freecopy of this organization’s annual report, please go tohttp://www.newswire.ca and click on Tools for Investors.
